stockrowNatera, Inc.
NTRA Healthcare Diagnostics & Research
Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.
- Revenue
- +34.1%
- EPS
- +34.4%
- Free cash flow
- −85.8%
- Total debt
- −0.06%
Quarter to September 2026, against a year earlier
Follow NTRA
Alert me
Natera, Inc. (NTRA) Revenue
Natera, Inc.'s revenue for fiscal 2025 was $2.3B, up 35.9% from $1.7B in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.9B. Over the past ten years it has ranged from $190.4M (fiscal 2015) to $2.3B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 8 consecutive fiscal years. Natera, Inc. ranks 14th of 47 Diagnostics & Research companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $2.3B | 35.90% |
| FY2024 | $1.7B | 56.75% |
| FY2023 | $1.1B | 31.99% |
| FY2022 | $820.2M | 31.13% |
| FY2021 | $625.5M | 59.97% |
| FY2020 | $391.0M | 29.33% |
| FY2019 | $302.3M | 17.34% |
| FY2018 | $257.7M | 22.91% |
| FY2017 | $209.6M | (1.36%) |
| FY2016 | $212.5M | 11.64% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $794.0M | 5.48% |
| Jun 2026 | $752.8M | 8.05% |
| Mar 2026 | $696.6M | 4.68% |
| Dec 2025 | $665.5M | 12.38% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| IQV IQVIA Holdings Inc. compare | $17.3B |
| LH Labcorp Holdings Inc. compare | $14.6B |
| DGX Quest Diagnostics Incorporated compare | $11.8B |
| A Agilent Technologies, Inc. compare | $7.4B |
| WAT Waters Corporation compare | $5.6B |
| IDXX IDEXX Laboratories, Inc. compare | $4.7B |
| ILMN Illumina, Inc. compare | $4.5B |
| MTD Mettler-Toledo International, Inc. compare | $4.1B |
| NTRA Natera, Inc. | $2.9B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on NTRA
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement